The Saudi Vaccine and Biomanufacturing Center (SVBC), the first of its kind in the Middle East, broke ground at KAUST on December 15. The center will develop vaccines and biopharmaceutical products under good manufacturing practice (GMP) standards. It is a joint project championed by the Ministry of Energy, Industry and Mineral Resources through the Industrial Clusters Program and supported by KACST. Why it matters: The center will serve as a national platform for pharmaceutical innovation and address epidemic risks in the Kingdom, such as MERS-CoV.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
Malaria No More, the Crown Prince Court of Abu Dhabi, and the Reaching the Last Mile program launched the Institute for Malaria and Climate Solutions (IMACS) to combat malaria amidst climate change. Mohamed Bin Zayed University for Artificial Intelligence (MBZUAI) joined as a technical partner, providing research support leveraging AI and data science. The initiative aims to develop and implement AI-driven strategies to address the impact of climate change on malaria transmission. Why it matters: This partnership highlights the UAE's commitment to using AI for global health challenges, particularly in combating climate-sensitive diseases like malaria.
KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.
MBZUAI is hosting a free webinar on August 4th from 6-7pm titled ‘How does AI help fight the COVID-19 pandemic?’. The webinar will be led by Dr. Mohammad Yaqub, Assistant Professor at MBZUAI, and will discuss the role of AI before, during, and after a pandemic. Registration is available at www.mbzuai.ac.ae/aitalks. Why it matters: This webinar aims to educate the public on the potential of AI in addressing pandemics, aligning with MBZUAI's social responsibility efforts in the UAE.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.